RxDoctor Payments Data

Aaron Hata, MD

Medical Oncology · Boston, MANPI 1518167758

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,008 of the $11,336 with a category attached, or 61.8%. 3 manufacturers reported payments, led by Amgen at 55.0% of the total.

$11,336in general payments, 2019–2025

Across 16 payments — averaging $708.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Pfizer$4K
  • Chugai Pharmaceutical Co., Ltd.$2K
$1,845,214in research payments, 2019–2025

Across 13 payments — averaging $141,940 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1M
  • Amgen$768K
  • Array Biopharma Inc$41K

What the payments were for

  • Consulting fees$7,00862%
  • Speaking & faculty fees$2,48022%
  • Travel & lodging$1,74715%
  • Food & beverage$1011%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen5$6,236
Pfizer10$3,580
Chugai Pharmaceutical Co., Ltd.1$1,520

How this compares

$11,336 in reported general payments places this provider in the 65th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$2,269
Medicare patients
13
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →